Cite
SGLT2 inhibitors for prevention of primary and secondary cardiovascular outcomes: A meta-analysis of randomized controlled trials.
MLA
He, Guijun, et al. “SGLT2 Inhibitors for Prevention of Primary and Secondary Cardiovascular Outcomes: A Meta-Analysis of Randomized Controlled Trials.” Heart & Lung : The Journal of Critical Care, vol. 59, May 2023, pp. 109–16. EBSCOhost, https://doi.org/10.1016/j.hrtlng.2023.02.009.
APA
He, G., Yang, G., Huang, X., Luo, D., Tang, C., & Zhang, Z. (2023). SGLT2 inhibitors for prevention of primary and secondary cardiovascular outcomes: A meta-analysis of randomized controlled trials. Heart & Lung : The Journal of Critical Care, 59, 109–116. https://doi.org/10.1016/j.hrtlng.2023.02.009
Chicago
He, Guijun, Guosu Yang, Xiaoyu Huang, Duan Luo, Chao Tang, and Zhen Zhang. 2023. “SGLT2 Inhibitors for Prevention of Primary and Secondary Cardiovascular Outcomes: A Meta-Analysis of Randomized Controlled Trials.” Heart & Lung : The Journal of Critical Care 59 (May): 109–16. doi:10.1016/j.hrtlng.2023.02.009.